Sabra Ayman, Bourgeois Marie, Blanc Emmanuelle, Fievez Stephane, Moïsi Jennifer, Goussiaume Gwenaël, Lemaitre Magali, Watier Laurence, Coulombel Nicolas, Tréhony Julien, Tricotel Aurore, Baghdadi Yasmine, Fartoukh Muriel S
Medical Affairs, Vaccines, Antivirals and Evidence Generation, Pfizer, Paris, France.
Vaccines Department, Pfizer, Paris, France.
Open Forum Infect Dis. 2024 Jun 28;11(7):ofae349. doi: 10.1093/ofid/ofae349. eCollection 2024 Jul.
Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality. The study objective was to describe the hospital burden of pneumonia in the adult population in France.
This retrospective study was conducted from the National Health Insurance Database. All hospitalizations for pneumonia (all-cause) between 2013 and 2019 were included. Different risk categories for patients were established based on pneumococcal vaccine recommendations by French health authorities.
A total of 2 199 240 episodes of CAP were registered over the study period (annual mean, 314 177 [standard deviation, 17 818.6]); 75% occurred in patients aged ≥65 years, among whom 47% were not classified in the moderate- or high-risk categories recommended for French pneumococcal vaccination. The incidence of CAP increased with age (117.9, 395.3, and 1916.7 per 100 000 for the age groups 18-49, 50-64, and ≥65 years, respectively, in 2019). Furthermore, being at risk of pneumococcal disease resulted in more severe outcomes, including longer episode duration (mean, 14 days in low-risk vs 17 days in high-risk patients) and higher risk of referral to critical care units (from 20% to 27%), of rehospitalization up to 180 days (from 39% to 67%), of in-hospital death (from 12% to 19%), and of 1-year mortality (from 26% to 49%).
This study establishes the incidence of CAP in adults in France, describes the significant burden of disease, and highlights the need for better prevention policies.
社区获得性肺炎（CAP）与显著的发病率和死亡率相关。本研究的目的是描述法国成年人群中肺炎的医院负担。
这项回顾性研究基于国家健康保险数据库开展。纳入了2013年至2019年间所有因肺炎（各种病因）住院的病例。根据法国卫生当局的肺炎球菌疫苗接种建议，为患者建立了不同的风险类别。
在研究期间共记录了2199240例CAP发作（年平均314177例[标准差，17818.6]）；75%发生在年龄≥65岁的患者中，其中47%未被归类为法国肺炎球菌疫苗接种建议的中风险或高风险类别。CAP的发病率随年龄增长而增加（2019年，18 - 49岁、50 - 64岁和≥65岁年龄组每10万人中的发病率分别为117.9、395.3和1916.7）。此外，肺炎球菌疾病风险导致更严重的后果，包括发作持续时间更长（低风险患者平均14天，高风险患者平均17天）以及转诊至重症监护病房的风险更高（从20%升至27%）、180天内再次住院的风险更高（从39%升至67%）、院内死亡风险更高（从12%升至19%）以及1年死亡率更高（从26%升至49%）。
本研究确定了法国成年人中CAP的发病率，描述了疾病的重大负担，并强调了制定更好预防政策的必要性。
